Company news

ARS Pharmaceuticals, Inc. news in 2026

ARS Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.

View company

ARS Pharma Reports Business Highlights and Third Quarter 2026 Financial Results

November 5, 2026

ARS Pharma to Report Third Quarter 2026 Financial Results

October 28, 2026

ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY

October 5, 2026

ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results

August 13, 2026

ARS Pharmaceuticals Announces Conference Call and Webcast on August 13 Outlining its Updated Strategic Priorities and Reporting Second Quarter 2026 Financial Results

August 3, 2026

ARS Pharmaceuticals Announces CEO Succession

July 7, 2026

ARS Pharmaceuticals Provides Commercial and Financial Updates

June 23, 2026

Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies

June 3, 2026

ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update

May 14, 2026

ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President

May 13, 2026

ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results

May 6, 2026

neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

April 14, 2026

ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy 1 mg Label

March 30, 2026

ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label

March 26, 2026

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization

March 8, 2026

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences

February 22, 2026

ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

February 10, 2026

EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg

February 1, 2026

ARS Pharmaceuticals, Inc. - California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use

January 22, 2026

California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use

January 20, 2026

Calls in 2026

Decks in 2026